News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Eli Lilly and Company (LLY)'s Solanezumab May Fail Pivotal Studies


7/30/2012 8:11:06 AM

Eli Lilly and Co's experimental drug solanezumab, which seeks to treat Alzheimer's disease, may fail its pivotal studies, Jefferies & Co said, downgrading the stock to "underperform" from "hold." Eli Lilly is expected to unveil by next month data from the highly anticipated studies on solanezumab, which has completed two late-stage trials. "We expect that solanezumab will outright fail its pivotal studies in Alzheimer's disease ... with only a 25 percent chance of being effective in a niche population," Jefferies analyst Jeffrey Holford said.

Read at Reuters
Read at BusinessWeek

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES